Going Upstream in Fibrosis: PMG1015, a First-in-Class Disease-Modifying Anti-Amphiregulin (AREG) Antibody for IPF

• AREG is a causal, upstream, epithelial-derived driver of fibrogenesis
• PMG1015 exhibited a well-tolerated safety profile with no dose limiting toxicities across three completed clinical studies
• In IPF, PMG1015 showed FVC stabilization and structural improvement on AI-quantified HRCT, supporting advancement into a global 52-week study

Speakers:

Nan Tang

CEO

Pulmongene